Literature DB >> 18325915

A new approach on bullous pemphigoid therapy.

Z Saouli, A Papadopoulos, G Kaiafa, F Girtovitis, Z Kontoninas.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18325915     DOI: 10.1093/annonc/mdn046

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  Rituximab for autoimmune blistering diseases: recent studies, new insights.

Authors:  L Lunardon; A S Payne
Journal:  G Ital Dermatol Venereol       Date:  2012-06       Impact factor: 2.011

2.  Treatment of subepidermal immunobullous diseases.

Authors:  Donna A Culton; Luis A Diaz
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

3.  Rituximab in severe skin diseases: target, disease, and dose.

Authors:  Daniel D Bennett; Maro Ohanian; Christian T Cable
Journal:  Clin Pharmacol       Date:  2010-07-07

4.  Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Authors:  Peng Cao; Wenjing Xu; Litao Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.